TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed, newly diagnosed or relapsed MALT, marginal zone lymphoma, or low-grade B cell lymphoproliferative disorder which is CD5-, CD10- and CD20+~* Pathology must be reviewed at Brigham \& Women's Hospital, Massachusetts General Hospital, or the University of Rochester James P. Wilmot Cancer Center prior to enrollment~* Documentation of CD20+ status~* Must not be a candidate for local radiotherapy with curative intent~* If gastric MALT, not a candidate for antibiotic therapy with curative intent~* Patients with leukemic phase marginal zone lymphoma are eligible if their absolute lymphocyte count is \>10,000 / µl~* Prior treatment with rituximab is permitted, if rituximab induced an objective response which persisted for at least 6 months~* Prior radiotherapy is acceptable~* Measurable disease~* ANC: \> 1000/mm3~* Platelets: \> 100,000/mm3~* Hemoglobin: \> 7 gm/dL~* Adequate renal function as indicated by serum creatinine \<= 2 mg/dL.~* Adequate liver function, as indicated by serum total bilirubin \<= 2 mg/dL.~* AST or ALT \<3x Upper Limit of Normal unless related to primary disease.~* Men and women of reproductive potential must agree to use an acceptable method of birth control during study treatment and for six months after completion of study treatment.~* WHO Performance status \</= 2~* Subject has provided written informed consent.~Exclusion Criteria:~* Patients with Waldenstrom's Macroglobulinemia or lymphoplasmacytic lymphoma are excluded~* History of HIV~* Active infection~* Known CNS disease~* Pregnant (a negative serum pregnancy test should be performed for all women of childbearing potential within 7 days of treatment) or currently lactating women~* Prior treatment within the last three weeks~* Prior fludarabine~* Positive direct antiglobulin test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fludarabine and Rituximab (Type: EXPERIMENTAL): Fludarabine:~25 mg/m2 on days 1-5 of 28 day cycle up to 6 cycles~Rituximab:~375 mg/m2 on day 1 of 28 day cycle up to 6 cycles Rituximab dose was split between days 1 and 3 for patients with absolute lymphocyte counts \> 10x10\^9/L~Patients received three cycles of therapy followed by re-staging with chest/ abdomen/ pelvic CT scan. Patients with progressive disease discontinued treatment. Patients with stable or responding disease continued therapy for another 3 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Laxative Effectiveness of a Phytotherapeutic Tea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* patients with 18 to 55 years old with chronic constipation according to the criteria of the American Association of Gastroenterology (AAG);~* patients should present good understanding and collaboration capacity, an not be in use of other medications with effects on the intestinal habit;~* patients with no abnormalities in the exams;~* willing to sign a written informed consent;~* women in fertile age should make use of appropriate anti-conception.~Exclusion Criteria:~* pregnant or breast feeding women;~* patients with history of abuse of alcohol or use of drugs;~* significant or not-controlled disease, except constipation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo/Laxative tea crossover (Type: ACTIVE_COMPARATOR): This arm received placebo in the first period and laxative tea in the second period (after washout period of 9 days).
- Laxative tea/Placebo crossover (Type: ACTIVE_COMPARATOR): This arm received laxative tea in the first intervention period and placebo in the second intervention period (after washout period of 9 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient Blood Management In CARdiac sUrgical patientS

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- all adult patients candidate to planned heart surgery~Exclusion Criteria:~* Pregnancy~* Know allergy to iron, or B vitamin, or folic acid~* Hyperferritinemia (ferritin blood value \> 300 ng/ml).~* patient's refusal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cases (Type: None): patients who fulfill the inclusion criteria
- controls (Type: None): Patients who underwent cardiac surgery in 2019 and 2018

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study for Patients With End-Stage Renal Disease (ESRD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ESRD patients requiring maintenance dialysis (haemodialysis, haemodiafiltration, haemofiltration, or peritoneal dialysis) for at least 1 month~* The mean of 2 iPTH determinations within 21 days before randomization and drawn at least 2 days apart must be greater than or equal to 300 pg/mL (31.8 pmol/L) and less than 800 pg/mL (84.8 pmol/L). If biPTH is determined, the mean levels must be greater than or equal to 150 pg/mL (15.9 pmol/L) and less than 410 pg/mL (43.5 pmol/L)~* The mean of 2 serum calcium determinations (corrected for albumin) drawn on the same day as the PTH determinations must be greater than or equal to 8.4 mg/dL (2.1 mmol/L)~Exclusion Criteria:~* Have an unstable medical condition, defined as having been hospitalised, other than for dialysis vascular access revision, within 30 days before day 1, or otherwise unstable in the judgment of the investigator~* Have had a parathyroidectomy in the 6 months before day 1~* Have received vitamin D therapy for less than 21 days before day 1 or required a change in prescribed vitamin D brand or dose within 21 days before day 1. If subjects are not prescribed vitamin D therapy, they must remain free of vitamin D therapy for the 21 days before day 1.~* Received, within 21 days before day 1 of the dose titration phase, therapy with medications that are predominantly metabolized by the enzyme CYP2D6 and have a narrow therapeutic index (e.g., flecainide, vinblastine, thioridazine, and most tricyclic antidepressants). The tricyclic antidepressant amitriptyline is permitted. - Experienced a myocardial infarction within 3 months prior to day 1~* Are currently enrolled in, or have not yet completed at least 30 days before day 1, other invasive investigational device or investigational drug trials, or are receiving other investigational agents (experimental dialysis machines are acceptable)~* Have a gastrointestinal disorder that may be associated with impaired absorption or orally administered medications or an inability to swallow tablets

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care (Type: NO_INTERVENTION): Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.
- Cinacalcet (Type: OTHER): Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg. Dose escalation of cinacalcet may occur based on iPTH values.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Previously undiagnosed patients with elevated PSA (ages 30-50 PSA \>2.5 ng/mL; ages 50-80 PSA \> 4ng/mL), eligible for prostate needle biopsy.~2. Patients can have negative prior needle biopsy(ies) for suspected prostate cancer~3. mpMRI with at least one suspicious target lesion (Arm A), or negative mpMRI but positive biopsy (Arm B).~4. Written informed consent~5. Age \> 30~Exclusion Criteria:~1. Age\> 80~2. Contraindication to MRI or prostate biopsy (e.g. extreme claustrophobia, metallic implants incompatible with MRI, anatomical contraindications, coagulopathy, severe medical comorbidity prohibiting halting of anticoagulation therapies)~3. Active urinary tract infection or indwelling catheter~4. Prior pelvic irradiation~5. Prior prostatectomy~6. Prior androgen deprivation hormonal therapy~7. Prostate biopsy within 8 weeks prior to study~8. Prior transurethral resection of the prostate (TURP)

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- PET/MRI before biopsy (Type: EXPERIMENTAL): Patients with suspected areas on mpMRI will undergo additional \[68Ga\]PSMA-11 PET/MRI scan with subsequent mpMRI and PET/MRI guided biopsy.
- PET/MRI after biopsy (Type: EXPERIMENTAL): Patients with unclear areas or a negative finding in the mpMRI for MRI guided biopsy but positive biopsy, which will undergo the additional \[68Ga\]PSMA-11 PET/MRI scan with \[68Ga\]PSMA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Electrically Evoked Compound Action Potentials Human Observation Medtronic Algorithm Comparison Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 22 years of age or older~* Candidate for or undergoing Medtronic SCS device trial for labeled indication - Candidate for or undergoing a Medtronic SCS device trial for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic SCS trialing to treat the patient's chronic pain. This decision is to be made prior to discussing with the patient whether to enroll in the study~* Willing and able to provide signed and dated informed consent~* Capable of comprehending and consenting in English~* Willing and able to comply with all study procedures and visits~* Clear, measurable ECAP ECAPs - If during set up of the in-clinic testing, the subject does not have a clear, measurable ECAP (\>10uV amplitude obtained consistently and repeatably) they will not move forward with testing or randomization and will be considered a screen failure.~Exclusion Criteria:~* Implanted electrical cardiac devices (e.g., pacemaker, defibrillator)~* Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)~* Pregnant or is of child-bearing potential and unwilling to use a medically acceptable form of birth control during the study~* Has untreated major psychiatric comorbidity, as determined by the investigator or designee~* Trialed with a permanent implant lead and extension (buried lead trial)~* If subject is classified as vulnerable or requires a legally authorized representative (LAR)

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-loop (OL) testing, then Closed-loop (CL) testing (Type: EXPERIMENTAL): Subjects receive Open-loop testing, then Closed-loop testing (Spinal Cord Stimulation - SCS Therapy)
- Closed-loop testing, then Open-loop testing (Type: EXPERIMENTAL): Subjects receive Closed-loop testing, then Open-loop testing (Spinal Cord Stimulation - SCS Therapy)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone to Increase Immune Function in People With HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV infected~* CD4 count 400 cells/mm3 or less~* HIV viral load less than 1000 copies/ml for 1 year prior to study entry; in some cases, viral load up to 5000 copies/ml will be acceptable~* Taking at least 2 anti-HIV medications~Exclusion Criteria:~* Diabetes~* Cancer. Patients with some cases of Kaposi's sarcoma or skin cancer will not be excluded.~* Some (not all) forms of heart disease~* Carpal Tunnel Syndrome~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Growth Hormone Arm (Type: EXPERIMENTAL): Growth hormone receipt in the first year, post-growth hormone follow-up in the second year
- 2 (Type: ACTIVE_COMPARATOR): Observation only in the 1st year, GH receipt in the second year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* previously untreated AML (excluding acute promyelocytic leukemia)~* age greater than 60 years old~* ECOG PS (Eastern Cooperative Oncology Group Performance scale) less than 2~* adequate hepatic/ renal/ cardiac function~Exclusion Criteria:~* acute promyelocytic leukemia~* significant cardiac disease~* combined non-hematologic malignancy~* aleukemic leukemia (only granulocytic sarcoma)~* CNS (Central Nervous system) involvement~* significant comorbidity/ uncontrollable bleeding tendency

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Asthmatic patients with pre-bronchodilatory FEV1 above 60% of predicted normal and above 1.5 liters.~* Men and post-menopausal women above 18 years of age.~* Reversible airway obstruction in response to classical beta2-agonist (salbutamol)~* Non/ex-smokers~Exclusion Criteria:~* Any clinically significant disease or disorder other than asthma~* Any clinically relevant abnormal findings at screening examinations~* Treatment with systemic glucocorticosteroids within the past 30 days~* Inhaled corticosteroid use if dosing is not kept constant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- crossover dose 1 (Type: EXPERIMENTAL): AZD3199 120 microgram
- crossover dose 2 (Type: EXPERIMENTAL): AZD3199 480 microgram
- crossover dose 3 (Type: EXPERIMENTAL): AZD3199 1920 microgram
- crossover dose 4 (Type: PLACEBO_COMPARATOR): Placebo
- crossover dose 5 (Type: ACTIVE_COMPARATOR): Formoterol 9 microgram
- crossover dose 6 (Type: ACTIVE_COMPARATOR): Formoterol 36 microgram

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~° Consecutive adult patients over 18 years of age scheduled to undergo VATS because of verified/suspected lung cancer.~Exclusion Criteria:~* Inability to understand verbal and written information.~* Preexisting chronic pain condition.~* Preoperative daily treatment with pain medication (Non-opioids, opioids, gabapentin/pregabalin).~* Previous thoracic surgery.~* Previous chemotherapy due to thoracic malignancy and / or radiation therapy. to the thorax.~* Pregnant women.~* Autoimmune neuromuscular diseases (sclerosis, peripheral neuromuscular disorders). General muscle weakness or atrophy.~* Hypersensitivity, allergy or intolerance to dexamethasone, bupivacaine or adrenaline.~* Preoperative epidural anaesthesia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Before implementation (Type: None): Perineural bupivacaine without adjuvants.
- After implementation (Type: None): Perineural bupivacaine with intravenous dexamethasone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatient, 18-70 years of age~* Currently meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for Generalized Anxiety Disorder~* Minimum score of 20 on Hamilton Rating Scale for Anxiety~Exclusion Criteria:~* Women who are pregnant or who will be breastfeeding during the study~* Patients with a history of:~  1. Any manic or hypomanic or mixed episode, including bipolar disorder and substance-induced manic, hypomanic or mixed episode~ 2. Any depressive episode with psychotic or catatonic features~ 3. Panic disorder with or without agoraphobia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Dose-matched placebo tablets, oral administration
- Vilazodone (Type: EXPERIMENTAL): Vilazodone tablets, oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Gene Therapy (On Trial)~Inclusion Criteria:~1. Diagnosis of ADA-SCID confirmed by DNA sequencing or by confirmed absence of \<3% of ADA enzymatic activity in peripheral blood (or for neonates) in umbilical cord blood erythrocytes and/or leukocytes or in cultured fetal cells derived from either chorionic villus biopsy or amniocentesis, prior to institution of Polyethylene glycol-modified ADA (PEG-ADA) replacement therapy~2. Patients who lack a fully Human leukocyte antigen (HLA)-matched family donor~3. Patients (male or female) \<5 years of age OR Patients (male or female) ≥ 5 years to 15 years of age who have preserved thymic function as evidenced by presence of \>10 % naïve T cells (CD4+45RA+27+ cells)~4. Parental/guardian signed informed consent~Exclusion Criteria:~1. Cytogenetic abnormalities on peripheral blood~2. Evidence of active malignant disease~3. Known sensitivity to busulfan~4. If applicable, confirmed pregnancy (to be tested in patients above 12 years old)~Gene Therapy (CUP)~A group of patients were treated under CUP (GOSH special license) either because the study was not yet open and patients needed urgent treatment, or because they were outside of the inclusion/exclusion criteria or received Investigational Medicinal Product (IMP) followed a different process (ie, received in two infusions). Patients followed the same protocol steps and study visits.~Historical Control Group~Inclusion Criteria:~1. Diagnosis of ADA-SCID confirmed by DNA sequencing OR by confirmed absence of \<3% of ADA enzymatic activity in peripheral blood or (for neonates) in umbilical cord blood erythrocytes and/or leucocytes or in cultured foetal cells derived from either chorionic villus biopsy or amniocentesis, prior to institution of PEG-ADA replacement therapy~2. Patients (male or female) between 0-18 years at time of treatment~3. Patient treated with allogeneic haematopoietic stem cell transplantation since 2000

- Gender: ALL
- Minimum Age: None
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Gene Therapy (Type: EXPERIMENTAL): Infusion of autologous EFS-ADA LV CD34+ cells
- Historical Control Group (Type: OTHER): Historical data from ADA-SCID patients who were treated with Hematopoietic Stem Cell Transplantation (HSCT)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete